Head to Head Survey: MindWalk (NASDAQ:HYFT) vs. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) and MindWalk (NASDAQ:HYFT) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.

Institutional and Insider Ownership

89.4% of Illumina shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 2.9% of Illumina shares are held by company insiders. Comparatively, 6.8% of MindWalk shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Illumina and MindWalk”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Illumina	$4.49 billion	9.17	$850.00 million	$5.36	50.94
MindWalk	$11.24 million	5.57	-$10.11 million	($0.26)	-5.15

Illumina has higher revenue and earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Illumina has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500. Comparatively, MindWalk has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500.

Profitability

This table compares Illumina and MindWalk’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Illumina	18.36%	29.84%	12.17%
MindWalk	-105.11%	-133.26%	-77.78%

Analyst Ratings

This is a summary of recent ratings and target prices for Illumina and MindWalk, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Illumina	2	6	10	0	2.44
MindWalk	1	1	2	1	2.60

Illumina currently has a consensus price target of $214.69, indicating a potential downside of 21.37%. MindWalk has a consensus price target of $5.00, indicating a potential upside of 273.13%. Given MindWalk’s stronger consensus rating and higher possible upside, analysts plainly believe MindWalk is more favorable than Illumina.

Summary

Illumina beats MindWalk on 11 of the 15 factors compared between the two stocks.

About Illumina

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.